How to use Technologies offered

A search for a cancer, preclinical stage, synthetic opportunity would use the selection "Therapeutics, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform Technology' in 'Sector' will identify all kinds of research technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each technology profile gives the name of a company or academic institute as source of the offer, and a link allowing to contact the potential licensor. In most cases a profile includes a pdf covering the available non-confidential information as well as detailed contact data.

Registered users can create non-public notifications profiles which will inform them about new 'Technologies Offered' entries fitting their needs as specified. In addition these profiles allow them to filter the available information more comfortably.

Name

Substances that enhance sensitivity/suppress resistance to TRAIL-based anti-cancer drugs

Organization name

PVA Saarland

Profile

Technical Summary

  • This technology is directed to enhancing the sensitivity to TRAIL-based anti-cancer drugs by suppressing TIP41 expression using TIP41 siRNA.
  • It has been confirmed that cancer cell-specific apoptosis is induced when a TRAIL-resistant cancer cell line is treated with TIP41 siRNA and then treated with TRAIL.
  • In vivo test completed

Technical Superiority

A TRAIL sensitizer capable of overcoming problems regarding the resistance to a cancer cell line-specific anti-cancer drug TRAIL

  • Proposed is a new technology to overcome resistance to the TRAIL anti-cancer drug.
  • Novel uses of a TIP41 gene and a TIP41 inhibitor were investigated.

Use as original technology to develop novel anti-cancer drugs

  • Presenting TIP41 as a new target for development of anti-cancer drugs in the future shows superior originality.
  • It has excellent innovativeness to be effectively used as anti-cancer supplement agent for preventing and treating cancer.

Major Technical Data

  • The apoptosis induced when a liver cancer cell line is transfected with TIP41 siRNA and then threated with TRAIL was confirmed.
  • Verification of functions of TIP41 siRNA using an animal test.

Please see flyer for further information.

Applications

  • TRAIL sensitizer field: anti-cancer sensitizing agents and anti-cancer supplement agents
  • Cancer-preventing and treatment field: anti-cancer drugs
  • Cancer diagnosis field: cancer diagnosis microarrays, cancer diagnosis biochips, cancer diagnosis kits, cancer diagnosis strips, cancer diagnosis reagents and other cancer diagnosis medical devices
  • Field for screening anti-cancer drugs or anti-cancer sensitizing agents: reagent for screening anti-cancer drugs or anti-cancer sensitizing agents, and diagnostic kits for screening anti-cancer drugs or anti-cancer sensitizing agents

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback

Please click here to log in to view the complete profile.

 
 

latest entries